Bolt Biotherapeutics reports Q2 2026 results, initial BDC-4182 data expected in Q3
Bolt said its Phase 1/2 trial of BDC-4182 in gastric and gastroesophageal cancer continues to enroll, with initial clinical data due alongside third-quarter results.
Bolt Biotherapeutics reported financial results for the quarter ended June 30, 2026, and gave a business update on August 11, 2026. CEO Willie Quinn said the company continued to make progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and gastroesophageal cancer, and is currently treating patients in Cohort 4.1 He added that BDC-4182 has been well tolerated to date, with activity consistent with the drug's immune-stimulating mechanism.1
The company said initial clinical data from the BDC-4182 Phase 1/2 study are expected with third quarter 2026 results.1 BDC-4182 is described as a next-generation Boltbody ISAC targeting claudin 18.2, a clinically validated target expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and other tumor types.1 Bolt noted that it has implemented step-up dosing, a strategy already used commercially for T-cell engagers, to reach higher doses safely,1 and that the trial is progressing with patients now being treated in Cohort 4 at the 4.0 mg/kg dose level.1
On the rest of the pipeline, Bolt said its other programs remain on hold, including BDC-3042, a Dectin-2 agonist that has finished a first-in-human Phase 1 dose-escalation study, along with preclinical ISAC candidates aimed at CEA and PD-L1.1 The company also said it has strategic collaborations with Genmab and Toray built around its Boltbody ISAC platform.1
On finances, Bolt held $18.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which it expects will fund operations into the first quarter of 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.